Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Muthoot Microfin IPO Date, Review, Price, Allotment Details

By Jagat Joshi
December 18, 2023

Muthoot Microfin IPO Details: Muthoot Microfin IPO date is fixed, the IPO is to hit the market on December 18 and will close on December 20. Muthoot Microfin IPO to raise around ₹960 crores via IPO that comprises fresh issue of ₹760 crores and offer for sale up to ₹200 crores of ₹10 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Muthoot Microfin Limited is a microfinance institution providing micro-loans to women customers (primarily for income generation purposes) with a focus on rural regions of India. They are the fourth largest NBFC-MFI in India in terms of gross loan portfolio as of December 31, 2022, as per CRISIL Report. They are also the third largest amongst NBFC-MFIs in South India in terms of the gross loan portfolio, the largest in Kerala in terms of MFI market share, and a key player in Tamil Nadu with an almost 16% market share, as of December 31, 2022, as per CRISIL Report.

As of March 31, 2023, Muthoot Microfin’s gross loan portfolio amounted to ₹92,082.96 million. As of March 31, 2023, the company has 2.77 million active customers, who are serviced by 10,227 employees across 1,172 branches in 321 districts in 18 states and union territories in India. Their branches are connected to our IT networks and are primarily located in commercial spaces which we believe are easily accessible by our customers.

They are a part of the Muthoot Pappachan Group, a business conglomerate with a presence across financial services, automotive, hospitality, real estate, information technology infrastructure, precious metals, and alternate energy sectors. The Muthoot Pappachan Group has a history of over 50 years in the financial services business. They are the second largest company under the Muthoot Pappachan Group, in terms of AUM for the Financial Year 2023. MFL, the flagship company of the Muthoot Pappachan Group, holds 54.16% of the pre-Offer Equity Share capital in our Company, on a fully diluted basis, as of the date of this Draft Red Herring Prospectus.

Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Fresh Issue towards augmenting the capital base to meet future capital requirements. The main objects and objects incidental and ancillary to the main objects set out in the Memorandum of Association enable the company:
(i) to undertake our existing business activities, and
(ii) to undertake the activities proposed to be funded from the Net Proceeds. Further, the Company expects to receive the benefits of listing the Equity Shares on the Stock Exchanges, including enhancing the brand image among existing and potential customers and creating a public market for the Equity Shares in India.

Muthoot Microfin IPO Review (Apply or Not)

Apply

Brokerage Firm IPO Review

Anand Rathi: Apply
Swastika Investmart: Apply

Muthoot Microfin IPO Date & Price Band Details

IPO Open:	December 18, 2023
IPO Close:	December 20, 2023
IPO Size:	Approx ₹960 Crores
Fresh Issue:	Approx ₹760 Crores
Offer for Sale:	Approx ₹200 Crores
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹277 to ₹291 Per Share
IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	₹14 per share for Employee
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here
Anchor Investors List:	Click Here

Muthoot Microfin IPO Market Lot

The Muthoot Microfin IPO minimum market lot is 51 shares with ₹14,841 application amount. The retail investors can apply up-to 13 lots with 663 shares or ₹192,933 amount.

Application	Lot Size	Shares	Amount
Retail Minimum	1	51	₹14,841
Retail Maximum	13	663	₹192,933
S-HNI Minimum	14	714	₹207,774
B-HNI Minimum	68	3,468	₹1,009,188

Muthoot Microfin IPO Allotment & Listing Dates

The Muthoot Microfin IPO date is December 18 and the close date is December 20. The Muthoot Microfin IPO allotment will be finalized on December 21 and the IPO listing on December 26.

Anchor Investors Allotment:	December 17, 2023
IPO Open Date:	December 18, 2023
IPO Close Date:	December 20, 2023
Basis of Allotment:	December 21, 2023
Refunds:	December 22, 2023
Credit to Demat Account:	December 22, 2023
IPO Listing Date:	December 26, 2023

You can check IPO subscription status and IPO allotment status on their respective pages.

Muthoot Microfin IPO Form

How to apply for the Muthoot Microfin IPO? You can apply for Muthoot Microfin IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Muthoot Microfin IPO in the Invest section. The other option is you can apply for Muthoot Microfin IPO via IPO forms downloaded via NSE and BSE. Check out the Muthoot Microfin forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.

Muthoot Microfin Company Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2021	₹696	₹687	₹7.05
2022	₹843	₹778	₹47.40
2023	₹1446	₹1233	₹163.89

Muthoot Microfin IPO Valuation – FY2023

Check Muthoot Microfin IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹14.19 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	10.08%
Net Asset Value (NAV):	₹139.15 per Equity Share

Peer Group

Equitas Small Finance Bank Limited
Ujjivan Small Finance Bank Limited
CreditAccess Grameen Limited
Spandana Sphoorty Financial Limited
Bandhan Bank Limited
Suryoday Small Finance Bank Limited
Fusion Micro Finance Limited

Company Promoters

Thomas John Muthoot
Thomas Muthoot
Thomas George Muthoot
Preethi John Muthoot
Remmy Thomas
Nina George
Muthoot Fincorp Limited

Muthoot Microfin IPO Registrar

Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: muthoot.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/

Muthoot Microfin IPO Allotment Status Check

Check Muthoot Microfin IPO allotment status on KFintech website allotment URL. Click Here

Muthoot Microfin IPO Lead Managers aka Merchant Bankers

ICICI Securities Limited
Axis Capital Limited
Jm Financial Limited
SBI Capital Markets Limited

Company Address

Muthoot Microfin Limited
13th Floor, Parinee Crescenzo,
Bandra Kurla Complex
Bandra East, Mumbai 400 051,
Phone: +91 48 4427 7500
Email: info@muthootmicrofin.com
Website: https://muthootmicrofin.com/

Muthoot Microfin IPO FAQs

What is Muthoot Microfin IPO?

Muthoot Microfin IPO is a main-board IPO. They are going to raise ₹960 Crores via IPO. The issue is priced at ₹277 to ₹291 pr equity share. The IPO is to be listed on BSE & NSE.

When Muthoot Microfin IPO will open?

The IPO is to open on December 18, 2023 for QIB, NII, and Retail Investors.

What is Muthoot Microfin IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Muthoot Microfin IPO?

You can apply for Muthoot Microfin IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Muthoot Microfin IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Muthoot Microfin”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Muthoot Microfin IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Muthoot Microfin”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Muthoot Microfin IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Muthoot Microfin”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Muthoot Microfin IPO Size?

Muthoot Microfin IPO size is ₹960 crores.

What is Muthoot Microfin IPO Price Band?

Muthoot Microfin IPO Price Band is ₹277 to ₹291.

What is the Muthoot Microfin IPO Allotment Date?

Muthoot Microfin IPO allotment date is December 21, 2023.

What is the Muthoot Microfin IPO Listing Date?

Muthoot Microfin IPO listing date is December 26, 2023. The IPO is to list on BSE and NSE.

Note: The Muthoot Microfin IPO price band and date are officially announced. The IPO grey market premium (Muthoot Microfin IPO Premium) will be added to the IPO grey market page as it will start).

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.